A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Doses of AL002 in Healthy Participants and in Participants With Mild to Moderate Alzheimer's Disease
Phase of Trial: Phase I
Latest Information Update: 26 Jul 2019
Price : $35 *
At a glance
- Drugs AL-002 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; First in man
- Acronyms INVOKE
- Sponsors Alector
- 28 Jan 2019 Planned number of patients changed from 52 to 67.
- 15 Nov 2018 Status changed from not yet recruiting to recruiting, according to an Alector media release.
- 23 Aug 2018 New trial record